Pharma BD Deal Intelligence
The acquisition combines Santaris Pharma's next-generation antisense technology and LNA expertise with Roche's deep experience in disease biology, chemistry,…
Evaluate noted Roche moved on Santaris under pressure of a potential IPO, paying $250M upfront for an LNA platform that had already produced Phase 2 candidates…
The Roche Innovation Center Copenhagen, the post-acquisition Santaris site, closed in 2023 with employees transitioning to Novo Nordisk - implying the LNA…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Roche acquired Copenhagen-based Santaris Pharma for $250M cash up front plus up to $200M in milestones, gaining the LNA antisense oligonucleotide platform. Strengthened Roche's RNA-targeted drug-discovery capabilities alongside its Genentech antibody franchise.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Santaris Pharma A/S (this deal) | 2014 | $450M | 26 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2014 deals · Roche Holding AG deals · Other deals